Autism stem cell therapy in Ukraine

Generally, parents notice signs of Autism very early before age 2 or 3. Mostly, motor milestones develop normally but delays can be observed. Parents might notice delays in speech and interactions or sometimes the speech develops but regresses thereafter.

As brain functioning is heavily involved in Autism, scientists and researchers have started looking at regenerative therapy using stem cells as potential therapy for Autism.

Recent studies have indicated that the lack of oxygen supply to the brain during or after birth and immune deregulation are the two important factors associated with Autism . These factors may result in decreased functioning of the brain or irregularities in the brain. This can cause an overarching imbalance in the brain which could get manifested as the carious symptoms of Autism.

Stem cells have the capability to multiply into many cells and form specialized cells different from the mother cell. This regeneration of cells can help in repairing the damaged brain tissue. Stem cells have the potential to repair the affected neural tissue at the molecular, structural and functional level. They are known to address the core of neuropathology of Autism with the help of their unique paracrine regulatory functions that are capable of regulating cell differentiation, tissue and organ repair, neurotrophic and anti-inflammatory actions in the recipient.

Results of the first phase of a clinical research regarding Autism therapy  by using stem cells

 And in early April 2017, Duke University officially published t results of the first phase of a clinical research on the safety of Autism stem cells treatment . It was  25 children of both sexes aged 2 to 5 years. Efficiency was registered by parents’ interviews and a number of clinical tests. It is reported that in more than 60% of the subjects there was a improvements of autism spectrum disorders (ASD) . Physicians start further research –  FDA approved double-blind, placebo-controlled study with 165 autistic children between the ages of 2 and 8 starts.

CNN showed a video of one family who took part in the trial and saw encouraging changes in her little daughter


Source – Stem Cells Translational Medicine 2017;6:1332–1339

Despite advances in early diagnosis and behavioral therapies, more effective treatments for children with autism spectrum disorder (ASD) are needed. We hypothesized that umbilical cord blood‐derived cell therapies may have potential in alleviating ASD symptoms by modulating inflammatory processes in the brain. Accordingly, we conducted a phase I, open‐label trial to assess the safety and feasibility of a single intravenous infusion of autologous umbilical cord blood, as well as sensitivity to change in several ASD assessment tools, to determine suitable endpoints for future trials. Twenty‐five children, median age 4.6 years (range 2.26–5.97), with a confirmed diagnosis of ASD and a qualified banked autologous umbilical cord blood unit, were enrolled. Children were evaluated with a battery of behavioral and functional tests immediately prior to cord blood infusion (baseline) and 6 and 12 months later. Assessment of adverse events across the 12‐month period indicated that the treatment was safe and well tolerated. Significant improvements in children’s behavior were observed on parent‐report measures of social communication skills and autism symptoms, clinician ratings of overall autism symptom severity and degree of improvement, standardized measures of expressive vocabulary, and objective eye‐tracking measures of children’s attention to social stimuli, indicating that these measures may be useful endpoints in future studies. Behavioral improvements were observed during the first 6 months after infusion and were greater in children with higher baseline nonverbal intelligence quotients. These data will serve as the basis for future studies to determine the efficacy of umbilical cord blood infusions in children with ASD.

Source – Stem Cells Translational Medicine 2017;6:1332–1339


contract research organization

stem cell therapy